Nektar Therapeutics (NKTR) Retained Earnings (2010 - 2026)
Nektar Therapeutics (NKTR) posted quarterly Retained Earnings of -$3.8 billion for Q1 2026, down 9756997.44% year-over-year from N/an in Q1 2025, and down 22383570.59% quarter-over-quarter from $17000.0 in Q4 2025.
Nektar Therapeutics (NKTR) Retained Earnings (2010 - 2026) Analysis & Trends
Nektar Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at -$3.8 billion for Q1 2026.
- In Q1 2026, Retained Earnings fell 9756997.44% year-over-year to -$3.8 billion; the TTM figure through Mar 2026 stood at -$3.8 billion (down 9756997.44% YoY), while the FY2025 annual figure was $17000.0, down 72.13% from the prior year.
- Retained Earnings for Q1 2026 stood at -$3.8 billion, down from $17000.0 in the prior quarter.
- The five-year high for Retained Earnings was $80000.0 in Q4 2023, with the low at -$3.8 billion in Q1 2026.
- The 5-year median for Retained Earnings is -$3.2 billion (2022), against an average of -$1.9 billion.
- The sharpest annual moves came in 2023 and 2026: Retained Earnings jumped 100.0% in 2023, then tumbled 9756997.44% in 2026.
- Nektar Therapeutics' Retained Earnings stood at -$3.2 billion in 2022, then soared by 100.0% to $80000.0 in 2023, then declined by 23.75% to $61000.0 in 2024, then slumped by 72.13% to $17000.0 in 2025, then sank by 22383570.59% to -$3.8 billion in 2026.
- Business Quant data shows NKTR's Retained Earnings at -$3.8 billion in Q1 2026, $17000.0 in Q4 2025, and -$3.7 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Nektar Therapeutics | 1.49 Bn | 919.46 Mn | 3.16 Mn | -3.81 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.81 Bn |
| Dec 31, 2025 | 17,000.00 |
| Sep 30, 2025 | -3.72 Bn |
| Jun 30, 2025 | -3.69 Bn |
| Mar 31, 2025 | 39,000.00 |
| Dec 31, 2024 | 61,000.00 |
| Sep 30, 2024 | -3.60 Bn |
| Jun 30, 2024 | -3.57 Bn |
| Mar 31, 2024 | -3.51 Bn |
| Dec 31, 2023 | 80,000.00 |
| Sep 30, 2023 | -3.44 Bn |
| Jun 30, 2023 | -3.39 Bn |
| Mar 31, 2023 | -5.68 Mn |
| Dec 31, 2022 | -3.20 Bn |
| Sep 30, 2022 | -8.17 Mn |
| Jun 30, 2022 | -8.19 Mn |
| Mar 31, 2022 | -6.53 Mn |
| Dec 31, 2021 | -4.16 Mn |
| Sep 30, 2021 | -2.69 Bn |
| Jun 30, 2021 | -2.56 Bn |